C0246

Cabergoline

≥98% (HPLC)

• 동의어(들): 1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea, 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, Cabaser, Dostinex, FCE-21336
• 실험식(Hill 표기법): C₂₆H₃₇N₅O₂
• CAS Number: 81409-90-7
• Molecular Weight: 451.60
• MDL number: MFCD00867887
• UNSPSC 코드: 12352200
• PubChem Substance ID: 329774771
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 양식: powder
• 광학 활성: [α]/D −63 to −74°, c = 0.5 in dichloromethane
• solubility: DMSO: ≥10 mg/mL
• 주관자: Johnson & Johnson
• 저장 온도: 2-8°C
• SMILES string: CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1
• InChI: 1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
• InChI key: KORNTPPJEAJQIU-KJXAQDMKSA-N
• 유전자 정보: human ... DRD2(1813)

설명

생화학적/생리학적 작용

Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).

특징 및 장점

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

안전성 정보

• 픽토그램: GHS07
• 신호어: Warning
• 유해 및 위험 성명서: H302,H362
• 예방조치 성명서: P202 - P260 - P263 - P264 - P301 + P312 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Lact.
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable